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Abstract 
Review on CASR, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: CAR, EIG8, FHH, FIH, GPRC2A, 
HHC, HHC1, NSHPT, PCAR1 
HGNC (Hugo): CASR 
Location: 3q21.1 
Local order: Chromosome: 3; NC_000003.11. 
Note 
Genbank Accession number: U20760; EMBL-Bank 
Accession number: X81086. 
DNA/RNA 
Description 
The human CaSR gene maps to 3q13.3-21, is 
approximately 103 kb in length and contains 8 
exons (exons 1A and 1B and exons 2-7) (Garrett et 
al., 1995; Janicic et al., 1995; Hendy et al., 2009). 
The full length CaSR protein is translated from part 
of exon 2, all of exons 3-6 and part of exon 7 
(Figure 1). Exons 1A and 1B are not translated. An 
alternatively spliced, functional variant of the 
receptor lacking exon 5 has been reported 
(Rodriguez et al., 2005a). The CaSR gene has two 
promoters, an upstream promoter (P1) containing a 
TATA box and CCAAT box and an additional 
promoter (P2) with Sp1 sites that cluster near the 
transcriptional start site (Figure 1; Chikatsu et al.,
2000; Canaff et al., 2008; Hendy et al., 2009). The
two promoters yield alternative transcripts 
containing either exon 1A or exon 1B spliced to  
exon 2 (Chikatsu et al., 2008; Hendy et al., 2009). 
Both promoters contain vitamin D response 
elements as well as response motifs for NF-κB and 
glial cells missing-2 (Canaff and Hendy, 2002; 
Canaff and Hendy, 2005; Canaff et al., 2009). The 
upstream promoter region contains Stat1/stat3 
elements which allow for response to interleukin-6 
(Canaff et al., 2008). Use of differential 
polyadenylation signals in exon 7 appear to lead to 
at least two different-sized 3' untranslated regions 
(Figure 1; Garrett et al., 1995). 
Protein 
Note 
The full length human CaSR mRNA encodes a 
protein of 1078 amino acids consisting of a 612 
amino acid signal peptide/extracellular domain 
(ECD), a 250 amino acid seven transmembrane 
domain (7TM) and an unusually long 216 amino 
acid intracellular tail (Garrett et al., 1995; Hu and 
Spiegel, 2003) (Figure 1). The NH2-terminal signal 
peptide is 19 amino acids in length and directs the 
nascent protein to the endoplasmic reticulum (ER) 
where it is subsequently removed (Hu and Spiegel, 
2003; Pidasheva et al., 2005; Hendy et al., 2009). 
The ECD is composed of a bilobed Venus flytrap 
(VFT) domain followed by a cysteine-rich domain 
connected via a peptide linker region to the 7TM 
which in addition to the membrane α-helices also 
contains three intra- and three extra-cellular loops; 
the final TM α-helix is connected to the 
intracellular tail, the membrane proximal domain of 
which is important for receptor cell expression and 
intracellular signalling (Ray et al., 1997; Hu and 
Spiegel, 2003).  






Atlas Genet Cytogenet Oncol Haematol. 2014; 18(4) 248 
 
Figure 1. Schematic representation of the calcium-sensing receptor (CaSR) gene structure (A), promoter location and 
features (B) and protein structural arrangement (C). The CaSR mRNA is transcribed from part of exon 2, all of exons 3 to 6 
and part of exon 7. Exons that comprise the CaSR protein are shaded yellow; untranslated exons are left unshaded. Note that 
intronic regions are not drawn to scale. The location of polyadenylation sites (AAA) within the untranslated region of exon 7 are 
arrowed. In B, the spatial relationship between promoters P1 and P2 (hatched) and untranslated exons 1A and 1B (unshaded) is 
highlighted along with the position of various transcription factor binding sites and regulatory elements: C, CCAAT box; T, TATA 
box; A, Ap-1 sites; *, serum response elements; VRE, vitamin D response elements; G, glial cells missing-2 response element; ↑, 
Sp1 sites; NFκB, NFκB response elements; S, STAT sites (S1 regulates IL-6 response). The CaSR protein (C) is composed of 
the extracellular domain (ECD) consisting of a signal peptide (SP), Venus Fly Trap (VFT) domain and cysteine-rich domain (Cys) 
connected by a small linker region (L) to the seven transmembrane domain (7TM) and intracellular tail, both encoded by exon 7. 
 
 
The CaSR protein is processed as a dimer in the ER 
via covalent intermolecular disulphide bonds and 
hydrophobic interactions and functions as a dimer 
when mature (Bai et al., 1998; Bai et al., 1999; 
Zhang et al., 2001; Pidasheva et al., 2006). 
Essentially, agonist binding to a cleft between the 
VFT lobes of each monomer leads to their closure 
and rotation about the VFT dimer interface thus 
transmitting a conformational change to the 
cysteine-rich domain which in turn allows 
movement of the 7TM α-helices with respect to one 
another resulting in connection of G proteins to the 
intracellular loops and initiation of signalling 
pathways (Hu and Spiegel, 2003).  
The CaSR contains 11 potential N- linked 
glycosylated sites in the ECD and is glycosylated in 
the ER with high mannose carbohydrates (immature 
receptor) after which it is transported to the Golgi 
where it is further modulated with complex 
carbohydrates (mature receptor) (Ray et al., 1998). 
Western blot analysis of protein extracted from 
cells containing mature and immature CaSR reveal 
bands at 150 kDa and 130 kDa, respectively.  
The CaSR contains five potential sites for protein 
kinase C phosphorylation, two in intracellular loops 
1 and 3 and three in the intracellular tail and two 
potential sites for protein kinase A phosphorylation 
in the intracellular tail (Garrett et al., 1995; Bosel et 
al., 2003). 
Description 
The CaSR was first cloned from bovine parathyroid 
cells by Brown and coworkers in 1993 and the 
human receptor was cloned from an adenomatous 
parathyroid gland in 1995 (Brown et al., 1993; 
Garrett et al., 1995).  
The CaSR is a G protein-coupled receptor 
belonging to Group II of Family C, G protein-
coupled receptors and conforms to a typical G 
protein-coupled receptor structure with a large 
extracellular domain, a seven transmembrane 
spanning domain and a rather large intracellular tail 
(Brown and MacLeod, 2001; Hu and Spiegel, 
2003).  
The CaSR is promiscuous, activating a variety of 
signalling pathways via a host of ligands (in 
addition to Ca2+) in a cell/tissue type-specific 
manner (Brown and MacLeod, 2001; Magno et al., 
2011b).  
The receptor's primary function is in the 
maintenance of calcium homeostasis in the body, 
but other functions have more recently come to 
light (see below). 
Expression 
The CaSR has a widespread tissue distribution in 
the body including those tissues which are 
important in the maintenance of calcium  
 






Atlas Genet Cytogenet Oncol Haematol. 2014; 18(4) 249 
homeostasis, namely the chief cells of the 
parathyroid gland where it is responsible for 
regulating parathyroid hormone (PTH) secretion, 
the C cells of the thyroid whereby it controls 
calcitonin secretion, the kidney where it controls 
calcium reabsorption, the placenta whereby it 
controls calcium transport from mother to foetus 
and in cartilage and bone cells, (chondrocytes, 
osteoblasts and osteoclasts) in which it has 
important effects on the laying down and 
maintenance of the skeleton (Magno et al., 2011b; 
Riccardi and Kemp, 2012). The CaSR is also 
expressed in intestinal epithelial cells where it 
serves to regulate intestinal uptake of calcium by 
directly modulating responsiveness to 1,25-
dihydroxyvitamin D (Egbuna et al., 2009). Apart 
from tissues which regulate calcium homeostasis, 
the CaSR is also expressed in many tissues outside 
this realm including the breast, ovary, uterus, testis, 
prostate and germ cells, the tongue, oesophagus, 
stomach and pancreas as well as the heart, various 
parts of the brain (including the subfornical organ 
and olfactory bulbs, hippocampus, hypothalamus 
and cerebellum), pituitary, lens epithelium and skin 
(Brown and MacLeod, 2001; Magno et al., 2011b; 
Riccardi and Kemp, 2012). The function of the 
CaSR in many of these tissues is still largely 
unknown. 
Localisation 
As expected for a G protein-coupled receptor, the 
CaSR localizes to the plasma membrane of the cells 
in which it is expressed. However, there is 
accumulating evidence for a large intracellular pool 
of receptor that localizes to the ER/Golgi awaiting 
agonist driven trafficking to the plasma membrane, 
a mechanism thought to regulate membrane CaSR 
abundance in the chronic presence of agonist (Grant 
et al., 2011). While the CaSR does undergo 
endocytosis and is targeted to the lysosome, it does 
not undergo substantial desensitization and 
recycling as occurs with many other G protein-
coupled receptors (Grant et al., 2011). In the chief 
cells of the parathyroid gland, CaSR is located in 
caveolae, flask-like invaginations of the plasma 
membrane that contain various signalling molecules 
and scaffolding proteins such as filamin-A and 
caveolin-1 to which the CaSR is anchored (Kifor et 
al., 1998). In various parts of the kidney tubule 
(proximal tubule, cortical thick ascending limb, 
distal convoluted tubule, medullary collecting duct) 
the membrane bound CaSR may be located apically 
or basolaterally or both depending on its specific 
function(s) in these compartments (Riccardi and 
Kemp, 2012). For example, the apically located 
CaSR in the medullary collecting duct inhibits 
insertion of AQP2 water channels and promotes 
activation of the B1 subunit of the vacuolar H+-
ATPase in the apical membrane, thus delivering a 
less concentrated and more acidified urine (Sands et 
al., 1998; Procino et al., 2004; Riccardi and Kemp, 
2012). Likewise in the gastrointestinal tract, the 
CaSR is expressed both on the apical and 
basolateral membranes of the gastrin secreting G 
cells of the stomach indicating that it can sense and 
respond to nutrient levels both in the lumen and in 
the blood, whereas CaSR in colonic epithelial cells, 
whether it is expressed apically or basolaterally, can
mediate cAMP-mediated fluid secretion (Conigrave 
and Brown, 2006). 
Function 
The primary function of the CaSR is in the 
maintenance of calcium homeostasis through 
regulation of PTH secretion and reabsorption of 
calcium from the kidney tubules. PTH has effects 
on bone resorption, intestinal uptake of calcium (via
production of 1,25-dihydroxyvitamin D) and 
calcium reabsorption from the kidney, all 
combining to restore calcium in the extracellular 
fluid to a concentration within the narrow range 1.1
- 1.3 mM Ca2+ (Tfelt-Hansen and Brown, 2005). 
However, the CaSR is now known to be a 
multifunctional receptor with important influences 
on major cellular processes that include not only 
entero-endocrine secretion but control of gene 
expression and cell differentiation, cellular 
proliferation, apoptosis, chemotaxis, cytoskeletal 
organization and the regulation of ion transport and
the activity of ion channels (Tfelt-Hansen and 
Brown, 2005; Riccardi and Kemp, 2012). It 
achieves this enormous diversity of function by 
activating an array of cell signalling pathways in a 
tissue and ligand-dependent manner, with partner 
binding proteins also playing an important role 
(Brennan and Conigrave, 2009; Magno et al., 
2011b). The CaSR can be activated not only by 
Ca2+ ions but by other di-, tri- and polyvalent 
cations including polyamines such as spermine, 
aminoglycoside antibiotics such as neomycin and 
polypeptides including amyloid β-peptide. Receptor 
activity is also modulated by pH and salinity and 
can be potentiated (in the presence of direct 
agonist) by allosteric activators such as L-amino 
acids and type II calcimimetics (Nemeth et al., 
1998; Conigrave et al., 2000; Brown and MacLeod, 
2001; Magno et al., 2011b). The receptor, upon 
activation, can couple to Gq/11, Gi/0, G12/13 and Gs G 
protein families to regulate a variety of signalling 
molecules including phosphatidylinositol-specific 
phospholipase C (PLC) (and hence PKC and 
release of intracellular Ca2+ from intracellular 
stores), as well as phospholipase A2, 
phosphatidylinositol 3-kinase (which in turn affects 
Akt signalling), phospholipase D and Rho and 
MAP kinases (including ERK1/ERK2) (Brennan 
and Conigrave, 2009; Magno et al., 2011b). When 
coupled to Gs and Gi the receptor can stimulate or 
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inhibit cAMP production, respectively 
(Mamillapalli et al., 2008).  
The precise pathway(s) involved in CaSR-mediated 
inhibition of PTH have yet to be completely 
elucidated, however the associated reduction in 
PTH mRNA levels involves an increase in 
intracellular Ca2+, suggesting a role for PLC 
activation (Ritter et al., 2008). The CaSR has 
several important homeostatic functions in the 
kidney depending on its location. In the proximal 
tubule, CaSR stimulation reverses the inhibitory 
effects of PTH on phosphate reabsorption via the 
phosphate transporters NaPi-IIa/NaPi-IIc and also 
blocks 2,5-hydoxyvitamin D3-1 α-hydroxylase. In 
the thick ascending limb of Henle's loop, 
stimulation of basolaterally localized CaSR reduces 
potassium cycling (by decreasing the activity of the
70-pS channel) as well as NaCl transport and 
paracellular reabsorption of Mg2+ and Ca2+. In the 
distal convoluted tubule, the CaSR is located both 
apically and basolaterally, in the former it is linked 
to the receptor potential vanilloid member 5 
(TPRV5) and stimulation of the CaSR therefore 
increases uptake of Ca2+ ions. Basolaterally, CaSR 
activation inhibits the activity of plasma membrane 
Ca2+-ATPase 1b and decreases expression of the 
K+ channel, Kir4.1 resulting in inhibition of 
basolateral K+ recycling. Activation of apically 
located CaSR in the medullary collecting duct 
reduces osmotic water permeability (creating less 
concentrated urine) by inhibiting vasopressin-
induced insertion of AQP2 water channels and 
increases the activity of H+ -ATPase (making urine 
more acidic). These effects reduce the likelihood of 
kidney stone formation (see recent reviews that 
discuss the functional homeostatic role for the 
receptor in the kidney by Magno et al., 2011b and 
Riccardi and Kemp, 2012). The CaSR is also 
expressed in regions of the kidney that do not relate 
to Ca2+ or other mineral ion homeostasis. Activation 
of the CaSR expressed in the juxtaglomerular cells 
of the afferent arteriole of the kidney inhibits 
release of renin, thus exerting influence over the 
renin-angiotensin system that controls blood 
pressure (Atchison et al., 2010) while stimulation of 
the CaSR in the podocytes of the glomerular filter 
has been shown to effect the cytoskeletal integrity 
and viability of these cells suggesting an important 
role for the receptor in proper renal filtration (Oh et 
al., 2011). 
The CaSR is expressed along the whole length of 
the gastrointestinal tract where it plays important 
roles in nutrient sensing, the regulation of fluid 
secretion, hormone release and cell 
differentiation/apoptosis (Conigrave and Brown, 
2006; Geibel and Hebert, 2009). Recent data show 
that taste buds contain the CaSR and that agonists 
of the CaSR enhance taste perception while 
antagonists of the CaSR suppress it (Ohsu et al., 
2010). The receptor is also expressed in the basal 
cells of the oesophagus where stimulation results in 
an increase in IL-8 secretion, the physiological 
importance of which is yet to be determined 
(Justinich et al., 2008). In the stomach, the CaSR 
plays a clear role in the regulation of gastrin and 
gastric acid release from G cells and parietal cells, 
respectively (Conigrave and Brown, 2006; Geibel 
and Hebert, 2009). In the duodenum, amino acid 
stimulation of the CaSR in I cells of the small 
intestine leads to release of cholecystokinin a 
hormone important for gall bladder contraction, 
pancreatic enzyme secretion and gastric emptying 
(Wang et al., 2011). CaSR expression in the acinar 
cells of the pancreas and in pancreatic duct cells 
suggests a role for the receptor in fluid secretion 
and/or the secretion of enzymes from the pancreas 
(Racz et al., 2002; Riccardi and Kemp, 2012). The 
proper regulation of fluid secretion from the 
pancreatic ducts by the CaSR is thought to be 
important in the prevention of pancreatic stones and 
pancreatitis (Riccardi and Kemp, 2012). In 
addition, activation of the CaSR expressed in the β-
cells of the pancreatic islets of Langerhans can 
modulate insulin secretion and this has implications 
for the onset and progression of diabetes (Gray et 
al., 2006; Squires et al., 2000). CaSR expression in 
colonic epithelial cells is required for the transition 
of cells along the crypt from a proliferative to a 
differentiated state, thus the presence of receptor in 
these cells is thought to be important in preventing 
colon cancer (Whitfield, 2009).  
Agonist activation of the CaSR in the colon can 
suppress cAMP-mediated fluid loss and is 
important in the control of NaCl and water 
absorption (Geibel and Hebert, 2009). It has been 
proposed that calcimimetics could be used to 
prevent diarrhoea/fluid loss associated with 
bacterial toxins in diseases such as cholera (Geibel 
et al., 2006). 
In the lactating breast, expression of the CaSR in 
mammary epithelial cells can regulate parathyroid 
hormone-related protein (PTHrP) production and 
adjust uptake of calcium into milk according to 
calcium availability (VanHouten et al., 2004). In 
the normal breast the CaSR has tumour suppressor 
properties acting in concert with the BRCA1 
tumour suppressor to decrease levels of the 
antiapoptotic protein, survivin, and increase 
sensitivity to paclitaxel, a drug commonly used in 
breast cancer treatment (Promkan et al., 2011). 
However, if expressed in malignant breast cells, the 
receptor may actually aid bone metastasis (see 
below under hypercalcaemia of malignancy). With 
relevance to its apparent role in metastasis, the 
CaSR has been shown to couple to integrins thereby 
promoting tumour cell adhesion and migration 
(Tharmalingham et al., 2011). The CaSR can also 
bind the focal adhesion protein, testin, that is 
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known to have important effects on cell spreading 
and motility (Magno et al., 2011a).  
In the brain, The CaSR is highly expressed in the 
subfornical organ and potentiates neuronal, 
hyperpolarization-activated inward currents, 
consistent with the bursting of action potentials in 
these neurons that has also been shown to be CaSR-
potentiated (Washburn et al., 2000; Yano et al., 
2004). The expression of the CaSR in the 
subfornical organ, which is a thirst control centre, 
suggests that the receptor plays a crucial role in 
fluid and electrolyte homeostasis. The CaSR also 
controls neuronal excitability in a number of other 
parts of the brain by regulating ion channels and 
this may contribute to its apparent role in epilepsy 
(Kapoor et al., 2008; Riccardi and Kemp, 2012). 
For example, in the hippocampus, CaSR-mediated 
activation of a voltage-independent Na+ leak 
conductance channel leads to neuronal excitation 
(Lu et al., 2010). In the hippocampus, increasing 
expression of the CaSR during the first weeks of 
life correlate with long-term potentiation indicating 
that the CaSR may play a role in cognitive 
functions such as memory and learning (Brown and 
MacLeod, 2001; Yano et al., 2004). The CaSR has 
important regulatory effects on the developing 
nervous system, for example, activation of the 
CaSR appears to be critical for the expansion and 
differentiation of oligodendrocyte progenitor cells 
and the generation of myelin in 
preoligodendrocytes (Chattopadhyay et al., 2008). 
Stimulation of CaSR is required for the production 
of a cofactor, tetrahydrobiopterin, essential for the
activation of nitrous oxide that is produced (in its
inactive form) in response to amyloid β peptide-
mediated activation of the receptor (Dal Pra et al., 
2005). Hence, CaSR may play an important role in 
late onset Alzheimer's disease that is characterized 
by nitrous oxide-mediated neuronal damage. In the 
pituitary gland, activation of the CaSR stimulates 
cAMP production via coupling to Gαs with 
subsequent secretion of PTHrP and ACTH 
(Mamillapalli and Wysolmerski, 2010). 
The CaSR is expressed and plays a functionally 
important role in various bone cells including 
osteoblasts/osteocytes and osteoclasts and their 
precursors, bone marrow derived stromal cells, 
monocyte-macrophage cells, chondrocytes and 
haematopoietic stem cells (Yamaguchi, 2008). 
Targeted depletion of the CaSR induced in mouse 
embryonic chondrocytes and osteoblasts has 
revealed that the CaSR is absolutely required for 
growth plate and skeletal development (Chang et 
al., 2008). Activation of the CaSR in osteoblasts i 
required for osteoblast differentiation, proliferation 
and mineralization (Yamaguchi, 2008; Dvorak-
Ewell et al., 2011). In addition, high Ca2+-induced 
apoptosis of osteoclasts is mediated through nuclear 
translocation of NF-κB which in turn is dependent 
on CaSR stimulation and activation of PLC 
(Mentaverri et al., 2006). The CaSR also appears to 
be important in osteoclastogenesis as shown in 
studies with bone marrow cells from CaSR 
knockout mice (Dvorak-Ewell et al., 2011). The 
CaSR is required for haemopoietic stem cells to 
lodge in the endosteal niche of the bone marrow - 
this has implications for the proper functioning of 
erythropoiesis (Adams et al., 2006). The CaSR 
appears to contribute, albeit indirectly, to the 
formation of teeth and the development of dental 
alveolar bone (Sun et al., 2010). 
The CaSR also has established roles in other organs 
and tissues including the heart and circulatory 
system. In the heart, the receptor can augment 
angiotensin II-mediated cardiac hypertrophy in 
cardiomyocytes, while CaSR-mediated production 
of nitrous oxide can lead to vasodilation in human 
aortic epithelial cells with subsequent effects on 
blood pressure (Ziegelstein et al., 2006; Wang et 
al., 2008). The CaSR has also been shown to 
mediate the cardio-protective effects of ischaemic 
preconditioning (Sun and Murphy, 2010). 
Expression of the CaSR in vascular smooth muscle 
cells of human arteries appears to be important in 
preventing arterial calcification (Alam et al., 2009). 
The CaSR appears to play an important role in the 
differentiation of keratinocytes and their survival 
(Tu et al., 2008). Lens epithelial cells express CaSR 
mRNA and protein and stimulation of the receptor 
regulates a calcium-activated potassium channel - it 
is likely that the receptor contributes to lens 
integrity (Chattopadhyay et al., 1997; Brown and 
MacLeod, 2001).  
The receptor also has functional effects on 
reproduction and development (Riccardi and Kemp, 
2012). The CaSR is expressed in ovarian surface 
cells and ova (where it is important for 
development and maturation), sperm (where it is 
important for maturation, motility and fertilization) 
and uterus (where it plays roles in implantation and
embryonic development). Hence its proper 
expression has important implications for fertility. 
In addition the receptor plays a critical role in the 
placenta and in embryonic and foetal development 
of organs such as the lung, brain and nervous 
system (Riccardi and Kemp, 2012). 
Homology 
The human and bovine CaSR share significant 
homology (greater than 90% at the amino acid 
level) with CaSRs from other mammals such as 
rodents, rabbits and cats (Garrett et al., 1995; 
Brown and MacLeod, 2001; Gal et al., 2010). Even 
CaSRs from chickens and the mudpuppy (an 
amphibian) share approximately 80% amino acid 
identity underscoring the functional importance of 
this receptor throughout the animal kingdom 
(Brown and MacLeod, 2001). The CaSR belongs to 
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Family C of the G protein-coupled receptors, 
members of which share at least 20% amino acid 
homology in their seven transmembrane domains 
(Brauner-Osborne et al., 2007). Group I of Family 
C comprise the metabotropic glutamate receptors 
(mGluR 1-8) whereas the CaSR belongs to Group II 
which also contains the vomeronasal and taste and 
odorant receptors and various orphan receptors 
including GPRC6A (the most closely related to the 
CaSR).  
Group III comprises the gammabutyric acid 
(GABAB) receptors). Interestingly, the CaSR can 
heterodimerize with mGluR and GABAB receptors 
resulting in receptor units with unique 
pharmacological profiles (Gama et al., 2001; Cheng 
et al., 2007).  
The ECD including the VFT of the Family C 
GPCRs shares homology with bacterial periplasmic 
nutrient-binding proteins (PBPs) and Family C 
GPCRs are thought to have evolved from fusion of 
an ancient PBP-like structure (forming the ECD) 
with an independently derived seven 




Heterozygous, germinal mutations in the CaSR may 
be activating or inactivating leading to the familial 
conditions of altered calcium sensing, autosomal 
dominant hypocalcaemia (ADH) and familial 
hypocalciuric hypercalcaemia (FHH), respectively 
(Pollak et al., 1993; Pollak et al., 1994). These 
disorders are usually benign and may often be 
asymptomatic, although in rare cases severe 
activating mutations of the CaSR may give rise to 
Bartter's syndrome subtype IV (Vargas-Poussou et 
al., 2002). On the other hand, the homozygous 
presence of inactivating mutations or compound 
heterozygous mutations affecting both alleles of the 
CaSR gene give rise to the rare, but much more 
serious condition, neonatal severe 
hyperparathyroidism (NSHPT), that normally 
requires surgical intervention (usually sub-total 
parathyroidectomy) in the neonate (Pollak et al., 
1993; Ward et al., 2004; Ward et al., 2012). 
Reported mutations leading to ADH and 
FHH/NSHPT number around 65 and 140, 
respectively and may occur almost anywhere in the 
CaSR gene coding region, although there is a 
particular preponderance in exons 3 and 4 which 
encode part of the extracellular ligand-binding 
domain that includes the VFT, and the 5' end of 
exon 7 which encodes the seven transmembrane, 
signalling domain, including the extra- and 





Increased dietary calcium has been shown to be 
protective against the development of breast cancer 
(Negri et al., 1996) and by contrast to the CaSR's 
positive role in breast cancer metastasis, the CaSR 
in general plays a tumour suppressor role in the 
development of breast cancer. This apparent 
paradox may best be explained by differences in the 
properties of primary as opposed to metastasing 
breast cancer cells (Ward et al., 2012). Agonist 
activation of the CaSR in breast cancer cells down-
regulates cell proliferation, cell invasion and 
anchorage-independent growth as well as 
expression of the anti-apoptotic protein, survivin, 
and affords an increase in sensitivity to paclitaxel, 
an important drug used in the treatment of breast 
cancer (Liu et al., 2009a). Interestingly, the BRCA1 
tumour suppressor gene which mimics these effects 
in breast cancer cells has been shown to do this by 
regulating the expression of the CaSR and therefore 
its effect on survivin expression and paclitaxel 
sensitivity (Promkan et al., 2011). 
Colon cancer 
Note 
As for breast cancer, calcium has been shown to be 
chemopreventative for colon cancer with high 
levels being inhibitory and low levels favourable to 
human colonic cell proliferation (Lipkin, 1999, 
Kallay et al., 2000). Moreover, the CaSR is 
expressed in human colonocytes and has been 
shown to mediate these proliferative events (Kallay 
et al., 2000; Kallay et al., 2003). This becomes 
significant within the colonic crypts where a 
concentration gradient which increases from the 
base to the apex of the crypt allows for early 
proliferation of stem cells at the base of the crypt 
and their subsequent differentiation to functional 
colonic epithelial cells and finally their 
apoptogenesis at the apex of the crypt (reviewed by 
Whitfield, 2009; Ward et al., 2012). This process i 
regulated in part by the CaSR which is expressed in 
cells in response to calcium as they move up the 
crypt. In turn, stimulation of the CaSR signals cells 
to stop dividing and start differentiating. This 
occurs primarily by CaSR-mediated suppression of 
components of the wnt signalling pathway such as 
β-catenin/TCF-4 which control nuclear cell cycle 
activators such as c-myc and cyclin D1 
(Chakrabarty et al., 2003; Whitfield, 2009). CaSR 
stimulation also produces E-cadherin which links 
up with β-catenin to form adherens junctions 
allowing cell-cell connections and at the same time 
sequestering β-catenin away from the nucleus 
(Bhagavathula et al., 2007). CaSR stimulation also 






Atlas Genet Cytogenet Oncol Haematol. 2014; 18(4) 253 
leads to increased expression of the cyclin-
dependent kinase inhibitors, p21 and p27, and 
down-regulates expression of the anti-apoptotic 
protein, survivin (Chakrabarty et al., 2005; Liu et 
al., 2009b). Taken together, it has been concluded 
that low levels of Ca2+ in the colon and/or a poorly 
expressed or functionally compromised CaSR could 
lead to a lack of control of cell proliferation in 
colonic crypt development leading to potential 
malignancy (Whitfield, 2009; Ward et al., 2012). 
Pancreatitis 
Note 
Chronic pancreatitis develops largely as a result of 
a build-up of trypsin resulting in tissue injury and 
inflammation. Hypercalcaemia associated with 
inactivating mutations of the CaSR might be 
expected to lead to high exposure of pancreatic 
acinar cells to Ca2+ leading to the activation of 
trypsinogen to trypsin and a reduction in 
chymotrypsin C-mediated degradation of trypsin 
(Racz et al., 2002; Whitcomb, 2010). Although 
inactivating CaSR mutations are sometimes 
associated with pancreatitis, no causal link between 
CASR/FHH and pancreatitis could be demonstrated 
(Stuckey et al., 1990; Pearce et al., 1996). However, 
there is a stronger association between concurrent 
mutations in the SPINK1 and CaSR genes and 
pancreatitis (reviewed by Whitcomb, 2010). The 
SPINK1 gene encodes a protein (serine protease 
inhibitor Kazal 1) that blocks trypsin in response to 
tissue inflammation. The current belief is that 
neither CASR nor SPINK1 gene mutations act 
alone to cause pancreatitis but together and/or in 
association with other factors appear to contribute 
to the pathogenesis of this disease (Whitcomb, 
2010). 
Primary and secondary 
hyperparathyroidism 
Note 
Primary hyperparathyroidism (PHPT) is most 
commonly caused by a single adenomatous 
parathyroid gland, although it can occasionally arise 
from double adenomas or hyperplasia of all four 
glands. The condition arises from suppression of 
the Ca2+-induced negative feedback mechanism that 
controls PTH secretion - essentially there is a 
higher set point for Ca2+-induced inhibition of PTH 
secretion (Cetani et al., 2000). Unlike the inherited 
disorders of calcium homeostasis described in the 
above section, CaSR mutations have not been 
associated with the adenomas that give rise to 
PHPT, rather mutations in other genes such as the 
MEN1 tumour suppressor and cyclin D1 oncogene 
predominate (Hosokawa et al., 1995; Sharretts and 
Simonds, 2010). However, adenomas associated 
with PHPT have been shown to express low levels 
of CaSR compared to normal parathyroid tissue 
(Kifor et al., 1996; Ward et al., 2012). While the 
reason for this reduced expression is unclear, it 
does lead to an exacerbation of the condition since 
the CaSR contributes to the altered set point for 
PTH release. In addition, there is further evidence 
for the involvement of the CaSR in PHPT: impaired 
CaSR-mediated amino acid sensing (as well as 
calcium sensing) can cause loss of negative 
feedback of PTH release (Mun et al., 2009) and 
specific allosteric activators of the CaSR 
(calcimimetics) have been used successfully in the 
treatment of PHPT (Peacock et al., 2009). Finally, 
various polymorphisms in the CaSR gene or its 
regulatory region have been linked to PHPT and/or 
the severity of its clinical manifestations (reviewed 
in Ward et al., 2012). Secondary 
hyperparathyroidism (SHPT) which most 
commonly arises from chronic kidney disease 
(CKD) is controlled by the CaSR as well as other 
factors that regulate calcium and phosphate 
homeostasis (Rodriguez et al., 2005b, Ward et al., 
2012). Essentially, in CKD, decreased phosphate 
excretion and decreased output of 1,25-
dihydroxyvitamin D (leading to decreased intestinal 
Ca2+ absorption) and skeletal resistance to PTH, 
result in hypocalcaemia which, through activation 
of the CaSR, leads to increased secretion of PTH 
(note that a decrease in both phosphate excretion 
and vitamin D production may also directly lead to 
increased PTH secretion). Parathyroid gland 
hyperplasia may then develop, leading to decreased 
expression of CaSR and further exacerbation of the 
hyperparathyroidism. As for PHPT, a rise in set 
point for Ca2+-induced control of PTH suppression 
occurs making SHPT amenable to treatment with 
calcimimetics (Cunningham et al., 2011). 
Hypercalcaemia of malignancy 
Note 
The CaSR plays a central role in hypercalcaemia of 
malignancy through the capacity of malignant cells 
expressing the CaSR to secrete PTHrP in response 
to agonist stimulation of the receptor (for reviews 
see Chattopadhyay, 2006, Ward et al., 2012). 
PTHrP acts like PTH to stimulate bone resorption 
and renal calcium reabsorption generating high Ca2+ 
concentrations which further stimulate the CaSR to 
secrete PTHrP, creating a vicious cycle. There are 
two types of hypercalcaemia resulting from 
malignancy, osteolytic hypercalcaemia and humoral 
hypercalcaemia (HHM), the former associated with 
bony metastases that act to directly resorb bone and 
the latter with solid tumours that secrete circulating 
factors that act to increase bone resorption. CaSR 
activation has been demonstrated to stimulate 
PTHrP in both breast and prostate cancer cell lines 
that metastasize to bone as well as in various solid 
tumours which are known to be associated with 
HHM: H-500 rat Leydig testicular cancer cells, a 
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human lung squamous cell carcinoma cell line and 
a human pancreatic cell line, (FA-6) (Sanders et al., 
2000; Sanders et al., 2001; Tfelt-Hansen, 2003; 
Morgan et al., 2006; Lorch et al., 2011). Expression 
of the CaSR appears to be an important 
predisposing factor for the generation and 
continued growth of bony metastases. Both breast 
and prostate cancer cells that express the CaSR at 
high levels have a greater tendency to metastasize 
to bone than those that express the receptor at low 
levels (Liao et al., 2006; Mihai et al., 2006). High 
Ca2+ concentrations act as a chemoattractant for 
breast cancer cells and this CaSR-dependent 
response positively correlates with the in vivo 
metastatic potential of several breast cancer cell 
lines (Saidak et al., 2009). In addition, high Ca2+ t 
bony metastases signalling through the CaSR may 
stimulate further growth of malignant cells, for 
example by activation of choline kinase and 
production of phosphocholine (Huang et al., 2009 ) 
or by regulating estrogen receptor-α expression and 
activity (Journe et al., 2004). In the prostate cancer 
cell line, PC-3, knockdown of the CaSR blocked 
Ca2+-enhanced proliferation and reduced metastatic 
progression in an athymic mouse model while Ca2+ 
stimulation enhanced PC-3 cell attachment, a 




There is mounting evidence that the CaSR plays an 
important role in the regulation of blood pressure. 
Stimulation of human aortic epithelial cells with 
spermine enhanced the production of nitrous oxide 
and this effect was prevented by siRNA- specific 
targeting of the CaSR, strongly suggesting a role 
for the receptor in vasodilation (Ziegelstein et al.,
2006). In addition, activation of the CaSR 
expressed in the juxtaglomerular cells of the 
afferent arteriole of the kidney inhibits release of 
renin, thus exerting influence over the renin-
angiotensin system that controls blood pressure 
(Atchison et al., 2010). Further to this, angiotensin 
II stimulates cardiac hypertrophy and this results in 
increased expression of the CaSR in the 
cardiomyocytes which, when activated, further 
drives angiotensin II-mediated hypertrophy (Wang 
et al., 2008; Magno et al., 2011b). The CaSR may 
also contribute to cardiac hypertrophy by IP3-
mediated increases in nuclear Ca2+ nd engagement 
of the CaN/NFAT pathway (Zhong et al., 2012). 
External stresses such as hypoxia-reoxygenation, 
ischaemia-reperfusion and the application of 
atherogenic agents have also been shown to 
increase CaSR expression in cardiac myocytes 
(reviewed in Magno et al., 2011b). Interestingly, 
the CaSR has been demonstrated to mediate the 
cardio-protective effects of ischaemic 
preconditioning (Sun and Murphy, 2010). The 
CaSR is also expressed in vascular smooth muscle 
cells of human arteries where its increased 
activation is associated with decreased 
mineralization (Alam et al., 2009). This is 
consistent with reduced expression of the CaSR in 
the atherosclerotic, highly calcified arteries found i  
patients with hypercalcaemia associated with 
secondary hyperparathyroidism and end stage CKD 
(Alam et al., 2009; Cunningham et al., 2011). 
Brain disease 
Note 
The CaSR is implicated to play a role in 
Alzheimer's disease (AD), with polymorphisms in 
intron 4 and exon 7 of the CaSR linked to AD 
status (Conley et al., 2009). Both amyloid-β peptide 
as well as apolipoprotein E protein can activate the 
CaSR with the former shown to have effects on 
calcium permeable, non-selective cation channels in 
hippocampal pyramidal neurons (Ye et al., 1997; 
Conley et al., 2009). Nitrous oxide is responsible 
for the neuronal cell death characterizing late onset 
AD and the CaSR is necessary for the generation of 
a cofactor (tetrahydrobiopterin) important in the 
activation of nitrous oxide that is produced (in its
inactive form) in response to amyloid-β peptide-
mediated stimulation of the receptor (Dal Pra et al., 
2005; Chiarini et al., 2009). The CaSR has also 
been linked to other brain diseases such as epilepsy 
with a mutation in the CaSR (R898Q) reported to 
cosegregate with idiopathic epilepsy in a family 
from Southern India (Kapoor et al., 2008). The 
CaSR appears to be critical for the expression of 
mRNA for myelin basic protein in 
preoligodendrocytes and therefore for proper 
myelination (Chattopadhyay et al., 2008) - in this 
respect it is likely that a non-functional CaSR could 
lead to impaired neurodevelopment. 
Bone disease 
Note 
The CaSR is expressed in osteoblasts/osteocytes 
and osteoclasts and their precursors, bone marrow 
derived stromal cells, monocyte-macrophage cells, 
chondrocytes and haematopoietic stem cells 
(reviewed by Yamaguchi, 2008). Expression of a 
functional CaSR is critical for growth plate 
development/endochronal bone formation, postnatal 
bone development and osteoblast differentiation 
and the effects on these processes are independent 
of CaSR-mediated PTH secretion (Brown and Lian, 
2008; Chang et al., 2008; Dvorak-Ewell et al., 
2011). The CaSR also appears to be important 
postnatally for proper teeth and dental alveolar bone 
formation (Sun et al., 2010) and upregulation of the 
CaSR in chondrocytes may contribute to the 
progression of osteoarthritis (Burton et al., 2005). 
While the CaSR has not been linked to the 
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development of osteoporosis, therapeutic agents 
such as strontium ranelate and calcilytic compounds 
which act through the CaSR have been used or 
proposed for its treatment (Trivedi et al., 2010; 
Marie et al., 2011). 
Other disease associations 
Note 
Activation of the CaSR expressed in the β-cells of 
the islets of Langerhans of the pancreas can 
modulate insulin secretion and hence the receptor 
may play a role in diabetes mellitus (Gray et al., 
2006; Squires et al., 2000). For example, L-
histidine activation of the CaSR appears to 
negatively modulate glucose-induced insulin 
secretion from β-cells through changes in spatial 
arrangement of the CaSR and L-type voltage-
dependent calcium channels that are important for 
Ca2+-dependent triggering of insulin release 
(Parkash and Asotra, 2011).  
Amino acid activation of the CaSR expressed in the 
I cells of the duodenum results in secretion of the 
hormone, cholecystokinin, which is important for 
the regulation of gall bladder contraction, 
pancreatic function, gastric emptying and satiety 
with the latter two having implications for obesity 
(Wang et al., 2011).  
In the kidney, proper regulation of AQP2 water 
channels and vacuolar H+-ATPase through 
activation of the CaSR in the collecting ducts is 
important for preventing kidney stones (Sands et 
al., 1998; Procino et al., 2004; Riccardi and Kemp, 
2012) and stimulation of the CaSR expressed in 
podocytes of the Bowman's capsule of the kidney 
glomerulus, helps maintain their cytoskeletal 
integrity and overall survival thus preventing 
glomerular disease including proteinuria (Oh et al., 
2011). 
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